| 1 |
Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A. Interferon-1b therapy in idiopathic pulmonary fibrosis: a mata-analysis. Chest 2005:128: 203-6
DOI
|
| 2 |
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-42
DOI
|
| 3 |
Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 1997:156:1897-901
DOI
ScienceOn
|
| 4 |
Date H, Tanimoto Y, Goto K, Yamadori I, Aoe M, Sano Y, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chst 2005:128:1364-70
|
| 5 |
Jegal Y, Kim DS, Shim TS, Lim C, Lee SD, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005:171:639-44
DOI
ScienceOn
|
| 6 |
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005:142:963-7
DOI
ScienceOn
|
| 7 |
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004:350:125-33.
DOI
ScienceOn
|
| 8 |
Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006:173:188-98
DOI
ScienceOn
|
| 9 |
Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long-term clinical effect of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Resp J 2006:28:496-504
DOI
ScienceOn
|
webmaster
